Somatostatin analogues (SSA) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) – Impact on glycemia and lipid profile in a monocentric series

#3782

Introduction: Somatostatin analogues (SSA) are often the first line therapy in neuroendocrine tumors (NET). The management of hyperglycaemia and dyslipidaemia are one of the most important challenges in healthcare. The impact of SSA on metabolic profile in GEP-NET is highly debated.

Aim(s): To evaluate the effects of SSA on glycemia and lipid profile in a monocentric series of GEP-NET.

Materials and methods: Serum total cholesterol, triglyceride and glucose levels were retrospectively evaluated before and after 6 and 12 months of SSA therapy, in a monocentric series of GEP-NET patients admitted from 2015 to September 2022 to the NET Unit of Federico II University of Naples (ENETS CoE). Patients with previous diagnosis of diabetes were excluded.

Conference:

Presenting Author: Cannavale G

Authors: Cannavale G, Benevento E, Minotta R, Liccardi A, Modica R,

Keywords: SSA, lipid profile, glycemia, GEP-NET, hyperglycaemia, Somatostatin analogues,